Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX2003 in Relapsed, Progressive, or Refractory B-Cell Malignancies
NCT07249905Phase 2Recruiting
- Sponsor
- ModeX Therapeutics
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- T-cell Engagers
- Countries
- 2
01
Overview
A Phase 2 trial of MDX2003 in B cell lymphoma, Waldenström macroglobulinemia (WM), sponsored by ModeX Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
MDX2003
03
Conditions
B cell lymphomaWaldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07249905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249905.